SDC, like prostate cancer (PCa), relies on the androgen receptor (AR) signalling pathway for tumour growth, and therefore androgen-receptor signalling inhibitors (ARSI) and androgen deprivation therapy (ADT) have been studied [2, 8]. This evidence concerns the gene AR and neoplasm.